Attilio Orazi, M.D.

Anatomic Pathology and Clinical Pathology
Attilio Orazi

Dr. Attilio Orazi, Professor of Pathology and Laboratory Medicine, serves as Vice Chairman for Hematopathology and Director, Division of Hematopathology. Dr. Orazi received his M.D. from the University of Milan in his native Italy. He completed postgraduate training in Hematology and Pathology in the United Kingdom and in Italy. Dr. Orazi is certified in Anatomic Pathology and in Hematology by the American Board of Pathology. Since emigrating to the United States, he has served as Professor of Pathology and Director of Hematopathology at the College of Physicians and Surgeons of Columbia University, in New York, and most recently in the same capacity, at the Indiana University School of Medicine.

Dr. Attilio Orazi is an internationally renowned academic hematopathologist whose diagnostic expertise spans all areas of hematopathology. However, he is best known for his expertise and scholarly accomplishments as a bone marrow pathologist. He is a member of the Scientific Committee of the European Bone Marrow Working Group, has directed courses concerning the assessment of bone marrow disorders and splenic pathology at the United States and Canadian Academy of Pathology and was the co-organizer of the 2007 Workshop of the Society of Hematopathology. Currently, Dr. Orazi is the main author or co-author in 14 chapter sections, including the vast majority of those concerning myeloid neoplastic disorders, in the upcoming 4th edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. He has published more than 130 peer-reviewed papers, numerous textbook chapters and review articles and is one of the two authors of the prominent textbook Disorders of the Spleen.

His research program is focused on identifying distinctive immunologic and molecular genetic characteristics of hematologic neoplasms that are useful in their diagnosis, classification, and prognosis. Additionally, his group is interested in elucidating the mechanisms that are involved in the pathogenesis of hematologic malignancies. On-going projects include:

1) The investigation of genetic alterations associated with malignant lymphoma and multiple myeloma and their subsequent evaluation as potential diagnostic and prognostic indicators.

2) The investigation of the molecular genetic events that underlie and are responsible for the clinical progression and morphologic transformation from low grade malignancies to clinically aggressive diseases.

3) The identification of the molecular genetic events responsible for the development of lymphoproliferative disorders in organ transplant recipients and their progression from oligoclonal proliferations responsive to diminished immunosuppression to autonomous monoclonal proliferations unresponsive to therapy.

4) The elucidation of molecular genetic events involved in the pathogenesis of myelodysplastic, myeloproliferative, and other types of myeloid neoplasms. The relationship between the presence of these abnormalities and the clinicopathologic manifestations are evaluated in an attempt to clarify controversial issues relevant to disease classification and clinical management of these patients.

Dr. Attilio Orazi serves as Professor and Vice Chairman for Hematopathology and Director of the Division of Hematopathology at the Weill Medical College of Cornell University and as Attending Pathologist at New York-Presbyterian Hospital. Dr. Orazi is

internationally recognized for his diagnostic expertise and for his many scholarly accomplishments

in hematopathology. He received his MD from the University of Milano School of Medicine, in Italy, completed residency training in clinical hematology and in pathology in the United Kingdom and in Italy, at both the University of Milano and Pavia. Dr. Orazi served as Director of Hematopathology in New York at the Columbia University College of Physicians and Surgeons and at Indiana University School of Medicine, Indianapolis, Indiana, before coming to the Weill Medical College. He has published more than 130 scientific papers and more than 30 book chapters primarily in hematopathology, is a active member of several international working groups, is actively involved in the writing group of the upcoming WHO Classification of Hematopoietic and Lymphoid Tissues Tumors, is the leading author of two textbooks, Disorders of the Spleen and Illustrated Pathology of the Bone Marrow, presents frequently courses on the same topics at the United States and Canadian Academy of Pathology, and overseas, and is a member of several Editorial Boards. Dr. Orazi is listed in "Who's Who in America" and "Who's Who in Medicine" Dr. Orazi is available to consult in all areas of hematopathology.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

 

Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB: Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large b-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, Vincristine, and prednisone. J Clin Oncol 30:3460-7, 2012.

Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, et al: Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: a report from an International DLBCL Rituximab-CHOP Consortium Program study. Blood Sep 5 [Epub ahead of print], 2012.

 

Thiele J, Orazi A, Kvasnicka HM, Franco V, Boveri E, Gianelli U, Gisslinger H, Passamonti F, Tefferi A, Barbui T: European bone marrow working group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 97:e5-6; discussion e7-8, 2012.

 

Tripodo C, Sangaletti S, Guarnotta C,  Piccaluga PP,  Cacciatore M,  Giuliano M, Franco G, Chiodoni C, Sciandra M, Miotti S, Calvaruso G, Vetri V,  Carè A, Florena AM, Scotlandi K, Orazi A, Pileri SA, Colombo MP: Stromal SPARC Contributes to the detrimental fibrotic changes associated with myeloproliferation while its deficiency favors myeloid cell expansion. Blood Sep 5 [Epub ahead of print], 2012.

 

Chiu A, Orazi A: Mastocytosis and mastocytic overlap syndromes. Sem Diagn Pathol 29:19-30, 2012.

 

Czader M, Orazi A: World Health Organization classification of myelodysplastic syndromes. Curr Pharm Des 18:3149-62, 2012.

 

Boiocchi L, Arabadjief M, Ghanima W, Bussel JB, Orazi A, Geyer JT: Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol  25:65-74, 2012.

 

Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, et al:  Patients with diffuse large B cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP consortium program study. Haematologica Aug 28. [Epub ahead of print], 2012.

 

Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A, Hasserjian RP: Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 26:751-61, June 2013.

 

Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM,Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, et al: CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121:2715-24, 2013.

Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, et al: Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4529-40, 2013. 

 

Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, et al: MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4021-31, 2013.

 

Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K, Orazi A, Bhagat G, His ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Møller MB, Young KH, Tzankov A: Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol Epub ahead of print], Jun 17, 2013.

Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R:  Advances in myelofibrosis: a clinical case approach. Haematologica 98:1499-509, 2013.

Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ: Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 122:1881-6, 2013.

Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA: IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Mod Pathol doi: 10.1038/modpathol.2013.159. [Epub ahead of print], 2013.

 

Honors and Awards

Laurea in Medicine Summa Cum Laude, University of Milan, Italy, 09/1979. Anatomic Pathology Summa Cum Laude, University of Pavia, Italy, 09/1987. Clinical and Laboratory Hematology Summa Cum Laude, University of Milan, Italy, 11/1991.The Best Doctors In New York, New York Magazine, 2010 <